STAT3 Pathway Targeting Type I Photosensitizer as an Immune Stimulator for Cancer Photoimmunotherapy

Area of Science:

• Oncology
• Immunology
• Photodynamic Therapy

Background:

• Signal transducer and activator of transcription 3 (STAT3) is hyperactivated in cancer, promoting proliferation and immunosuppression.
• Inhibiting STAT3 enhances T cell-mediated antitumor immunity.
• Immunogenic cell death (ICD) induction is crucial for T cell infiltration into tumors.

Purpose of the Study:

• To investigate Stains-All (SA) as a STAT3 pathway targeting photosensitizer.
• To evaluate the synergistic effects of SA-induced ICD and STAT3 inhibition in cancer therapy.
• To repurpose SA as a novel photoimmune stimulator for synergistic tumor ablation.

Main Methods:

• Utilized Stains-All (SA), a cationic carbocyanine dye, as a type I photosensitizer.
• Investigated SA's ability to trigger immunogenic apoptosis and pyroptosis in tumor cells.
• Assessed the impact of SA on STAT3 activation and antitumor immune responses in vivo.

Main Results:

• SA effectively triggered tumor cell immunogenic death and provoked antitumor immune responses.
• SA inhibited STAT3 activation, preventing tumor growth and immune escape.
• Combined ICD induction and STAT3 inhibition by SA synergistically suppressed primary and distant tumor growth.

Conclusions:

• Stains-All (SA) acts as a novel photoimmune stimulator targeting the STAT3 pathway.
• SA demonstrates potent synergistic effects in tumor ablation through ICD induction and STAT3 inhibition.
• This study highlights the potential of repurposing SA for advanced cancer immunotherapy.